Thrice-weekly maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS)  by Mallolas, Josep et al.
Letters t o  t h e  E d i t o r s  2 1 3  
2. Steinbrink K. T h e  case for revislon arthroplasty u ing  
antibiotic-loaded acrylic cement. Clin Orthop Re1 Res 
1990; 261: 19-22. 
3. Gerhart TN, Roux RD, Hanff PA, Horowitz GL, Kenshaw 
AA, Hayes WC. Antibiotic-loaded biodegradable bone 
crmcnt for prophylaxis and treatment of experimental 
osteomyelitis in rats. J Orthop Res 19?3; 11: 250-5. 
4. Reese RE, Betts RE Antibiotic use. In:  Reese KE, Betts 
RF, eds. A practical approach to infectious diseases, third 
edition. Boston: Little, Brown and Co, 1?91: 821-1007. 
5. Abbott Laboratories Diagnostic Division. TDx" system 
assays I. North Chicago, IL: Abbott Laboratories, 1992. 
6. Scyral P. Zannicr A, Argenson JN, Raoult D. The release in 
vituo of vancornycin and tobraniycin from acrylic cement. J 
Antimicrob Chernothrr 1?94; 33: 337-9. 
7. Popharn GJ, Mangino P, Seligson D, Henry SL. Antiblotic- 
impregnated beads. Part 11: Factors in antibiotic selection. 
Orthop Rev 1991; 20: 331-7. 
8. Askew MJ, Kufel MF, Fleissner PK Jr, Gradisar IA Jr, 
Salstroni S, Tan JS. Effect of vacuum n i i x i q  on  the 
mechanical properties of antibiotic-impregnated poly- 
niethylmethacrylate bone cement. J Biomed Mater Res 
1990; 24: 573-80. 
Thrice-weekly maintenance therapy for 
cytomegalovirus retinitis in patients with acquired 
immunodeficiency syndrome (AIDS) 
To the Editors: 
Cytomegalovirus (CMV) retinitis is the most common 
localization of CMV disease in patients with acquired 
imniunodeficiency syndrome (AIDS) and is, in fact, the 
most frequent ocular opportunistic infection, often 
leading to a partial or total loss of vision [I ] .  Induction 
treatment for CMV disease is relatively well stan- 
dardized (2 to 3 weeks of daily intravenous ganciclovir 
or foscarnet) and able to control the progression of the 
retinitis in approximately 60 to 80% of cases [2,3]. With- 
out maintenance therapy, the relapse rate approaches 
100% within 3 to 6 weeks. Even with maintenance 
therapy with ganciclovir (5 mg/kg/day) or foscarnet 
(120 nig/kg/day) daily for 5 daydweek, 50% of 
patients relapse after a median time of 8 to 16 weeks 
[4,5]. It has been suggested that doubling the dose of 
ganciclovir (to 10 nig/kg/day), but with thrice-weekly 
administration, may be as effective as the standard 
dosage of 5 days/week [6,7]. To follow is our report of 
the results of an open, prospective, clinical study of 
maintenance therapy, using the thrice-weekly 
approach, for CMV retinitis in AIDS patients. 
A total of 69 human immunodeficiency virus 
(HIV)-infected adults diagnosed with CMV disease 
between May 1988 and December 1993 were eligible 
for inclusion in the study. Those who had CMV 
retinitis (M = 57), with or without other localizations, 
were given at least 2 weeks of intensive induction 
therapy with eithcr intravenous ganciclovir (5 ing/kg 
every 12 h), foscarnet (60 mg/kg every 8 h) cir both. 
O f  these 57 patients, 33 successfully completed the 
induction treatment, gave their conscnt to receive 
intravenous maintenance therapy thrice weekly and 
were included in the study. Maintenance therapy was 
started with either ganciclovir (10 mg/kg/day) or 
foscarnet (1 00 nig/kg/day) or both, every Monday, 
Wednesday and Friday, for a mean period of 19 
(range 6 to 78) weeks. The crude relapse rate was 51% 
(17/33) and the crude mortality rate was 66%) (22/33). 
Altogether, 27 patients received ganciclovir (1 4 relapses, 
28 deaths), four received foscarnet (two relapses, two 
deaths), and two patients received both (one relapse, 
two deaths). The time to relapse of CMV retinitis, time 
to death or relapse and time to death are shown in 
Figure 3 .  The median time to relapse was 18 weeks, 
the median survival time free of CMV retinitis was 14 
weeks and the median survival time was 34 weeks. 
Neutropenia occurred in eight patients (24%,), seven 
receiving ganciclovir and one receiving foscarnet, and 
anemia occurred in two patients (6%,), both of whom 
were receiving ganciclovir. No changes in therapy were 
required. The neutropenia was con trolled using granulo- 
cyte colony-stimulating factor and the anemia with 
blood transfusion when required. 
Treatment with either drug improved median 
survival time from the time of CMV diagnosis to 6 to 
8 months to almost 1 year in those responding to anti- 
CMV treatment. Maintenance therapy i q  mandatory to 
delay relapse and progression to blindness. The  median 
time to relapse has been reported to range from 2 to 4 
weeks without maintenance therapy and from 8 to 19 
weeks with daily or 5 days/week maintenance therapy 
[4,5]. Both ganciclovir and foscarnet appear to be 
equally effective in preventing relapses, although in at 
least one study, foscarnet significantly increased survival 
time (by around 4 months) coinpared with ganciclovir 
[4). Hall and colleagues [6] and Ganveg and coworkers 
[7] have reported that a total weekly dose of 30 mg/kg 
of ganciclovir, distributed in three, five or seven doses, 
has similar efficacy in preventing relapses. Our results 
are in agreement with these studies and emphasize that 
the thrice-weekly approach does not appear to be 
worse in ternis of survival. Ganciclovir therapy is often 
complicated by severe neutropenia, thereby requiring 
temporary or permanent discontinuation or niodifica- 
tion of dosage in a t  least 25% of patients. In our study, 
eight (24%) of 29 patients developed moderate neutro- 
penia that did not require discontinuation of therapy. 
Thus, the toxicity rate was similar to that seen with 
standard therapy (5 nig/kg/day for 5 days/week). 
At present, oral ganciclovir i s  being evaluated as 
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maintenance therapy for CMV retinitis and the pre- 
liminary results are promising, with similar efficacy to 
that of standard regimens of intravenous ganciclovir 
delivered 5 or 7 daydweek. As the number of AIDS 
patients with CMV retinitis is increasing, more patients 
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Figure 1 Survival and control of CMV retinitis in 33 study 
patients receiving thrice-weekly maintenance ganciclovir or 
foscarnet therapy: (A) Time without retinitis progression (17 
patients progressed, 16 censored; median 18 weeks); (B) Time of 
survival free of retinitis (25 patients died or relapsed, 8 censored; 
median 14 weeks); (C) Time of survival from diagnosis of retinitis 
(22 patients died, 11 censored median 34 weeks). 
will need maintenance therapy. A thrice-weekly 
approach is clearly more comfortable for the patients 
and less time-consuming. Our study indicates that this 
hypothesis should be further tested in a prospective 
randomized trial. 
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Infection caused by Ochrobactrum anthropi 
To the Editors: 
Ochrobactvum anthropi (formerly Centers for Disease 
Control group Vd), Alcaligenes xylosoxidans subspecies 
xylosoxidans, and Agrobacterium radiobacter belong to 
the former genus Achromobacter [l]. These pathogens 
are glucose-non-fermentative, non-fastidious, oxidase- 
positive, motile (by peritrichous flagella) gram-negative 
